CoChat

Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis

Commons, Robert J, Rajasekhar, Megha, Edler, Peta, Abreha, Tesfay, Awab, Ghulam R, Baird, J Kevin, Barber, Bridget E, Chu, Cindy S, Cui, Liwang, Daher, André, Gonzalez-Ceron, Lilia, Grigg, Matthew J, Hwang, Jimee, Karunajeewa, Harin, Lacerda, Marcus V G, Ladeia-Andrade, Simone, Lidia, Kartini, Llanos-Cuentas, Alejandro, Longley, Rhea J, Pereira, Dhelio B, Pasaribu, Ayodhia P, Pukrittayakamee, Sasithon, Rijal, Komal R, Sutanto, Inge, Taylor, Walter R J, Thanh, Pham V, Thriemer, Kamala, Vieira, José Luiz F, Watson, James A, Zuluaga-Idarraga, Lina M, White, Nicholas J, Guerin, Philippe J, Simpson, Julie A, Price, Ric N, Adhikari, Bipin, Anstey, Nicholas M, Assefa, Ashenafi, Boyd, Sarah C, Chau, Nguyen Hoang, Day, Nicholas PJ, Degaga, Tamiru Shibiru, Dondorp, Arjen M, Erhart, Annette, Ferreira, Marcelo Urbano, Ghimire, Prakash, Green, Justin A, Koh, Gavin CKW, Mekuria, Asrat Hailu, Mueller, Ivo, Naadim, Mohammad Nader, Nelwan, Erni J, Nosten, Francois, Price, David J, Sattabongkot, Jetsumon, Stepniewska, Kasia, von Seidlein, Lorenz, William, Timothy, Woodrow, Charles J, Woyessa, Adugna · 2024 · The Lancet Infectious Diseases
Cited by 61

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(23)00430-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 49

  1. Commons, 2020, Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis, Am J Trop Med Hyg, 103, 1094, 10.4269/ajtmh.20-0186 · DOI · Paper page
  2. Thriemer, 2021, Towards the elimination of Plasmodium vivax malaria: implementing the radical cure, PLoS Med, 18, 10.1371/journal.pmed.1003494 · DOI
  3. Saint-Yves, 1977, Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands, P N G Med J, 20, 62
  4. Krudsood, 2008, High-dose primaquine regimens against relapse of Plasmodium vivax malaria, Am J Trop Med Hyg, 78, 736, 10.4269/ajtmh.2008.78.736 · DOI
  5. Rajgor, 2014, Antirelapse efficacy of various primaquine regimens for Plasmodium vivax, Malar Res Treat, 2014
  6. Saravu, 2018, A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in south India, Malar J, 17, 321, 10.1186/s12936-018-2472-5 · doi:10.1186/s12936-018-2472-5
  7. Pukrittayakamee, 2010, A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand, Am J Trop Med Hyg, 82, 542, 10.4269/ajtmh.2010.09-0428 · doi:10.4269/ajtmh.2010.09-0428
  8. Chamma-Siqueira, 2022, Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 386, 1244, 10.1056/NEJMoa2104226 · DOI · Paper page
  9. Commons, 2017, The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials, Int J Parasitol Drugs Drug Resist, 7, 181, 10.1016/j.ijpddr.2017.03.003 · DOI
  10. Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
  11. Battle, 2014, Geographical variation in Plasmodium vivax relapse, Malar J, 13, 144, 10.1186/1475-2875-13-144 · DOI · Paper page
  12. Hasugian, 2007, Dihydroartemisinin–piperaquine versus artesunate–amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria, Clin Infect Dis, 44, 1067, 10.1086/512677 · DOI · Paper page
  13. Barber, 2013, A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy, Clin Infect Dis, 56, 383, 10.1093/cid/cis902 · DOI · Paper page
  14. Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study, Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
  15. Pasaribu, 2013, A randomized comparison of dihydroartemisinin–piperaquine and artesunate–amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia, J Infect Dis, 208, 1906, 10.1093/infdis/jit407 · DOI
  16. Gonzalez-Ceron, 2015, Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico, Malar J, 14, 426, 10.1186/s12936-015-0938-2 · DOI
  17. Lidia, 2015, Therapeutic effects of dyhidroartemisinin piperaquine versus chloroquine for uncomplicated vivax malaria in Kupang, East Nusa Tenggara, Indonesia, Int J Pharm Sci Rev Res, 31, 247
  18. Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia, BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
  19. Yuan, 2015, Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar, Antimicrob Agents Chemother, 59, 1230, 10.1128/AAC.04270-14 · DOI · Paper page
  20. Longley, 2016, High efficacy of primaquine treatment for Plasmodium vivax in western Thailand, Am J Trop Med Hyg, 95, 1086, 10.4269/ajtmh.16-0410 · DOI
  21. Zuluaga-Idárraga, 2016, Prospective study of Plasmodium vivax malaria recurrence after radical treatment with a chloroquine–primaquine standard regimen in Turbo, Colombia, Antimicrob Agents Chemother, 60, 4610, 10.1128/AAC.00186-16 · DOI
  22. Abreha, 2017, Comparison of artemether–lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial, PLoS Med, 14, 10.1371/journal.pmed.1002299 · DOI · Paper page
  23. Awab, 2017, Chloroquine–primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial, Am J Trop Med Hyg, 97, 1782, 10.4269/ajtmh.17-0290 · DOI · Paper page
  24. Chu, 2018, Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine–primaquine in Plasmodium vivax malaria, Clin Infect Dis, 67, 1543, 10.1093/cid/ciy319 · DOI · Paper page
  25. Daher, 2018, Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial, Malar J, 17, 45, 10.1186/s12936-018-2192-x · doi:10.1186/s12936-018-2192-x
  26. Grigg, 2018, Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors of severity, Clin Infect Dis, 67, 350, 10.1093/cid/ciy065 · DOI
  27. Chu, 2019, Chloroquine versus dihydroartemisinin–piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria, Clin Infect Dis, 68, 1311, 10.1093/cid/ciy735 · DOI
  28. de Sena, 2019, Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin, Malar J, 18, 439, 10.1186/s12936-019-3072-8 · DOI
  29. Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
  30. Ladeia-Andrade, 2019, Monitoring the efficacy of chloroquine–primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil, Antimicrob Agents Chemother, 63, e01965, 10.1128/AAC.01965-18 · DOI · Paper page
  31. Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
  32. Rijal, 2019, Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal, J Infect Dis, 220, 448, 10.1093/infdis/jiz126 · DOI · Paper page
  33. Thanh, 2015, Confirmed Plasmodium vivax resistance to chloroquine in central Vietnam, Antimicrob Agents Chemother, 59, 7411, 10.1128/AAC.00791-15 · DOI
  34. Pereira, 2016, Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment, Malar J, 15, 477, 10.1186/s12936-016-1530-0 · DOI
  35. Edgcomb, 1950, Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report, J Natl Malar Soc, 9, 285
  36. Pukrittayakamee, 1994, Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria, J Infect Dis, 169, 932, 10.1093/infdis/169.4.932 · DOI
  37. Bunnag, 1994, High dose of primaquine in primaquine resistant vivax malaria, Trans R Soc Trop Med Hyg, 88, 218, 10.1016/0035-9203(94)90305-0 · doi:10.1016/0035-9203(94)90305-0
  38. Baird, 2019, 8-aminoquinoline therapy for latent malaria, Clin Microbiol Rev, 32, e00011, 10.1128/CMR.00011-19 · DOI · Paper page
  39. 2013, The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin–piperaquine: a pooled analysis of individual patient data, PLoS Med, 10
  40. Barnes, 2006, Sulfadoxine–pyrimethamine pharmacokinetics in malaria: pediatric dosing implications, Clin Pharmacol Ther, 80, 582, 10.1016/j.clpt.2006.08.016 · DOI · Paper page
  41. Chu, 2021, Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria, Antimicrob Agents Chemother, 65, 10.1128/AAC.01302-21 · doi:10.1128/aac.01302-21
  42. Douglas, 2017, Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study, PLoS Med, 14, 10.1371/journal.pmed.1002379 · DOI · Paper page
  43. Dinelly, 2021, Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria, Malar J, 20, 266, 10.1186/s12936-021-03793-0 · DOI
  44. de Pina-Costa, 2021, Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases, Malar J, 20, 341, 10.1186/s12936-021-03869-x · doi:10.1186/s12936-021-03869-x
  45. Thriemer, 2018, Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group, Malar J, 17, 241, 10.1186/s12936-018-2380-8 · DOI · Paper page
  46. Clayman, 1952, Toxicity of primaquine in Caucasians, J Am Med Assoc, 149, 1563, 10.1001/jama.1952.72930340022010b · doi:10.1001/jama.1952.72930340022010b
  47. Chu, 2017, Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens, PLoS Med, 14, 10.1371/journal.pmed.1002224 · DOI · Paper page
  48. Rajasekhar, 2023, Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis, Lancet Infect Dis
  49. White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malaria J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page

Cited by

See all 61

Metadata

Authors
Commons, R. J., Rajasekhar, M., Edler, P., Abreha, T., Awab, G. R., Baird, J. K., Barber, B. E., Chu, C. S., Cui, L., Daher, A., Gonzalez-Ceron, L., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Lidia, K., Llanos-Cuentas, A., Longley, R. J., Pereira, D. B., Pasaribu, A. P., Pukrittayakamee, S., Rijal, K. R., Sutanto, I., Taylor, W. R. J., Thanh, P. V., Thriemer, K., Vieira, J. L. F., Watson, J. A., Zuluaga-Idarraga, L. M., White, N. J., Guerin, P. J., Simpson, J. A., Price, R. N., Adhikari, B., Anstey, N. M., Assefa, A., Boyd, S. C., Chau, N. H., Day, N. P., Degaga, T. S., Dondorp, A. M., Erhart, A., Ferreira, M. U., Ghimire, P., Green, J. A., Koh, G. C., Mekuria, A. H., Mueller, I., Naadim, M. N., Nelwan, E. J., Nosten, F., Price, D. J., Sattabongkot, J., Stepniewska, K., von Seidlein, L., William, T., Woodrow, C. J., & Woyessa, A.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2024-02
Volume
24
Issue
2
Pages
172-183
ISSN
1473-3099
Cited by
61
References
1
Language
en
Licence
Funders
  • National Health and Medical Research Council (2017436, 2008501, 2016792, 1196068, 1194702)
  • Bill & Melinda Gates Foundation
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (093956/Z/10/C, 223253/Z/21/Z)
  • Capability Systems Centre
  • Centers for Disease Control and Prevention
  • Wellcome Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(23)00430-9
The paper
Commons, R. J., Rajasekhar, M., Edler, P., Abreha, T., Awab, G. R., Baird, J. K., Barber, B. E., Chu, C. S., Cui, L., Daher, A., Gonzalez-Ceron, L., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Lidia, K., Llanos-Cuentas, A., Longley, R. J., . . . Woyessa, A. (2024). Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(23)00430-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.